The test aims to deliver pathogen identification and antibiotic susceptibility results directly from lower respiratory specimens in hours rather than days.
Pattern Bioscience announced that its Pneumonia ID/AST Panel is being evaluated at five clinical microbiology laboratories across the US through the company’s Early Evaluation Program.
The program gives laboratory directors, medical laboratory scientists, and their clinical partners hands-on experience with Pattern’s platform in their own labs. Feedback from participating sites on workflow, integration pathways, and usability will inform the company’s plans for commercial introduction of the system. Additional laboratories are in the planning phase, and Pattern expects the program to expand in the coming months.
“We appreciate the partnership of our early evaluation sites. Through these collaborations, we will continue to learn how laboratories will integrate the Pattern system into their routine workflow, and we will generate additional data to help quantify the potential impact of the platform,” says Carey-Ann Burnham, PhD, CEO of Pattern Bioscience, in a release.
Addressing Delays in Pneumonia Diagnosis
Pneumonia is a leading cause of sepsis and carries among the highest mortality of sepsis-related infections, according to the company. Laboratories and clinicians often wait two to four days for conventional culture-based methods to return pathogen identification and antimicrobial susceptibility results. Pattern says this delay can contribute to prolonged ICU stays, suboptimal antibiotic use, and the spread of antimicrobial resistance.
The Pneumonia ID/AST Panel is designed to provide the information laboratories and clinicians typically obtain from culture to support a pneumonia diagnosis: which organism is causing the infection and which antibiotics will treat it. The assay delivers bacterial detection, identification, and antimicrobial susceptibility results in one test, directly from lower respiratory tract specimens. It runs on Pattern’s single-cell microbiology platform, which is designed to return results in hours rather than the days culture requires.
Pattern’s products are for Investigational Use Only and have not been cleared by the FDA. Results generated during the Early Evaluation Program are not used for patient management.
Regulatory Status
The FDA has granted the Pneumonia ID/AST Panel Breakthrough Device Designation. Subject to FDA clearance, Pattern plans to launch the panel as its first commercial product. Breakthrough Device Designation does not constitute FDA clearance or approval, and it does not guarantee that the agency will clear or approve the device or do so within a particular timeframe.
Pattern Bioscience is a privately held company based in Austin, Texas. Its single-cell microbiology technology is a direct-from-specimen, rapid phenotypic testing platform.
ID 468595203 © Skypixel | Dreamstime.com